COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Ethics
2.3. Clinical Assessment
2.4. COMT and NRG1 Genotyping
2.5. Statistic Analysis
3. Results
3.1. Descriptive Analysis
3.2. Impact of Genetic Polymorphisms on Clinical Characteristics
3.3. Impact of Genetic Polymorphisms on Treatment Response
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Foster, A.; Miller, D.D.; Buckley, P. Pharmacogenetics and Schizophrenia. Clin. Lab. Med. 2010, 30, 975–993. [Google Scholar] [CrossRef]
- Gupta, S.; Jain, S.; Brahmachari, S.K.; Kukreti, R. Pharmacogenomics: A Path to Predictive Medicine for Schizophrenia. Pharmacogenomics 2006, 7, 31–47. [Google Scholar] [CrossRef] [PubMed]
- Elsheikh, S.S.M.; Müller, D.J.; Pouget, J.G. Pharmacogenetics of Antipsychotic Treatment in Schizophrenia. In Pharmacogenomics in Drug Discovery and Development; Yan, Q., Ed.; Methods in Molecular Biology; Springer: New York, NY, USA, 2022; Volume 2547, pp. 389–425. Available online: https://link.springer.com/10.1007/978-1-0716-2573-6_14 (accessed on 7 June 2024).
- Love, R.C.; Nelson, M.W. Pharmacology and clinical experience with risperidone. Expert Opin. Pharmacother. 2000, 1, 1441–1453. [Google Scholar] [CrossRef] [PubMed]
- Davis, J.M.; Chen, N. Clinical Profile of an Atypical Antipsychotic: Risperidone. Schizophr. Bull. 2002, 28, 43–61. [Google Scholar] [CrossRef] [PubMed]
- Chopko, T.C.; Lindsley, C.W. Classics in Chemical Neuroscience: Risperidone. ACS Chem. Neurosci. 2018, 9, 1520–1529. [Google Scholar] [CrossRef] [PubMed]
- Azorin, J.-M.; Spiegel, R.; Remington, G.; Vanelle, J.-M.; Péré, J.-J.; Giguere, M.; Bourdeix, I. A Double-Blind Comparative Study of Clozapine and Risperidone in the Management of Severe Chronic Schizophrenia. Am. J. Psychiatry 2001, 158, 1305–1313. [Google Scholar] [CrossRef]
- Olfson, M.; Gerhard, T.; Huang, C.; Lieberman, J.A.; Bobo, W.V.; Crystal, S. Comparative Effectiveness of Second-Generation Antipsychotic Medications in Early-Onset Schizophrenia. Schizophr. Bull. 2012, 38, 845–853. [Google Scholar] [CrossRef]
- Caligiuri, M.P.; Teulings, H.-L.; Dean, C.E.; Niculescu, A.B.; Lohr, J. Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone. Hum. Mov. Sci. 2009, 28, 633–642. [Google Scholar] [CrossRef]
- Shalbafan, M.; Saeedi, V.; Kamalzadeh, L. Significant improvement of risperidone-induced retrograde ejaculation on drug holidays: A case report. Psychiatry Clin. Psychopharmacol. 2019, 29, 120–122. [Google Scholar] [CrossRef]
- Hodkinson, A.; Heneghan, C.; Mahtani, K.R.; Kontopantelis, E.; Panagioti, M. Benefits and harms of Risperidone and Paliperidone for treatment of patients with schizophrenia or bipolar disorder: A meta-analysis involving individual participant data and clinical study reports. BMC Med. 2021, 19, 195. [Google Scholar] [CrossRef]
- Peuskens, J.; Pani, L.; Detraux, J.; De Hert, M. The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review. CNS Drugs 2014, 28, 421–453. Available online: http://link.springer.com/10.1007/s40263-014-0157-3 (accessed on 7 June 2024). [CrossRef] [PubMed]
- Balijepalli, C.; Druyts, E.; Zoratti, M.J.; Wu, P.; Kanji, S.; Rabheru, K.; Yan, K.; Thorlund, K. Change in Prolactin Levels in Pediatric Patients Given Antipsychotics for Schizophrenia and Schizophrenia Spectrum Disorders: A Network Meta-Analysis. Schizophr. Res. Treat. 2018, 2018, 1–9. [Google Scholar] [CrossRef]
- Yoshimura, R.; Nakamura, J.; Shinkai, K.; Goto, M.; Yamada, Y.; Kaji, K.; Kakihara, S.; Ueda, N.; Kohara, K.; Ninomiya, H.; et al. An open study of risperidone liquid in the acute phase of schizophrenia. Hum. Psychopharmacol. Clin. Exp. 2005, 20, 243–248. [Google Scholar] [CrossRef]
- Álamo, C. Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review. Adv. Ther. 2022, 39, 4875–4891. [Google Scholar] [CrossRef]
- Schooler, N.R. Negative symptoms in schizophrenia: Assessment of the effect of risperidone. J. Clin. Psychiatry 1994, 55, 22–28. [Google Scholar] [PubMed]
- Bravo-Mehmedbasic, A. Risperidone in the treatment of schizophrenia. Med. Arh. 2011, 65, 345–347. [Google Scholar] [CrossRef] [PubMed]
- Agarwal, S.M.; Dissanayake, J.; Agid, O.; Bowie, C.; Brierley, N.; Chintoh, A.; De Luca, V.; Diaconescu, A.; Gerretsen, P.; Graff-Guerrero, A.; et al. Characterization and prediction of individual functional outcome trajectories in schizophrenia spectrum disorders (PREDICTS study): Study protocol. PLoS ONE 2023, 18, e0288354. [Google Scholar] [CrossRef]
- Kahn, R.S.; Sommer, I.E.; Murray, R.M.; Meyer-Lindenberg, A.; Weinberger, D.R.; Cannon, T.D.; O’Donovan, M.; Correll, C.U.; Kane, J.M.; Van Os, J.; et al. Schizophrenia. Nat. Rev. Dis. Primer 2015, 1, 15067. [Google Scholar] [CrossRef] [PubMed]
- Owen, M.J.; Sawa, A.; Mortensen, P.B. Schizophrenia. Lancet 2016, 388, 86–97. [Google Scholar] [CrossRef]
- Tandon, R.; Gaebel, W.; Barch, D.M.; Bustillo, J.; Gur, R.E.; Heckers, S.; Malaspina, D.; Owen, M.J.; Schultz, S.; Tsuang, M.; et al. Definition and description of schizophrenia in the DSM-5. Schizophr. Res. 2013, 150, 3–10. [Google Scholar] [CrossRef]
- Buonocore, M.; Inguscio, E.; Bosinelli, F.; Bechi, M.; Agostoni, G.; Spangaro, M.; Martini, F.; Bianchi, L.; Cocchi, F.; Guglielmino, C.; et al. Disentangling Cognitive Heterogeneity in Psychotic Spectrum Disorders. Asian J. Psychiatry 2021, 60, 102651. [Google Scholar] [CrossRef] [PubMed]
- Wójciak, P.; Rybakowski, J. Clinical picture, pathogenesis and psychometric assessment of negative symptoms of schizophrenia. Psychiatr. Pol. 2018, 52, 185–197. [Google Scholar] [CrossRef] [PubMed]
- Andreasen, N.C. Ventricular Enlargement in Schizophrenia Evaluated With Computed Tomographic Scanning: Effects of Gender, Age, and Stage of Illness. Arch. Gen. Psychiatry 1990, 47, 1008. [Google Scholar] [CrossRef] [PubMed]
- Galderisi, S.; Merlotti, E.; Mucci, A. Neurobiological background of negative symptoms. Eur. Arch. Psychiatry Clin. Neurosci. 2015, 265, 543–558. [Google Scholar] [CrossRef] [PubMed]
- Glausier, J.R.; Lewis, D.A. Dendritic spine pathology in schizophrenia. Neuroscience 2013, 251, 90–107. [Google Scholar] [CrossRef] [PubMed]
- Tendilla-Beltrán, H.; Antonio Vázquez-Roque, R.; Judith Vázquez-Hernández, A.; Garcés-Ramírez, L.; Flores, G. Exploring the Dendritic Spine Pathology in a Schizophrenia-related Neurodevelopmental Animal Model. Neuroscience 2019, 396, 36–45. [Google Scholar] [CrossRef]
- Stefansson, H.; Sarginson, J.; Kong, A.; Yates, P.; Steinthorsdottir, V.; Gudfinnsson, E.; Gunnarsdottir, S.; Walker, N.; Petursson, H.; Crombie, C.; et al. Association of Neuregulin 1 with Schizophrenia Confirmed in a Scottish Population. Am. J. Hum. Genet. 2003, 72, 83–87. [Google Scholar] [CrossRef] [PubMed]
- Stefansson, H.; Steinthorsdottir, V.; Thorgeirsson, T.; Gulcher, J.; Stefansson, K. Neuregulin 1 and schizophrenia. Ann. Med. 2004, 36, 62–71. [Google Scholar] [CrossRef] [PubMed]
- Corvin, A.P.; Morris, D.W.; McGhee, K.; Schwaiger, S.; Scully, P.; Quinn, J.; Meagher, D.; St Clair, D.; Waddington, J.L.; Gill, M. Confirmation and refinement of an ‘at-risk’ haplotype for schizophrenia suggests the EST cluster, Hs.97362, as a potential susceptibility gene at the Neuregulin-1 locus. Mol. Psychiatry 2004, 9, 208–212. [Google Scholar] [CrossRef]
- Williams, N.M.; Preece, A.; Spurlock, G.; Norton, N.; Williams, H.J.; Zammit, S.; O’Donovan, M.C.; Owen, M.J. Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Mol. Psychiatry 2003, 8, 485–487. [Google Scholar] [CrossRef]
- Fukui, N.; Muratake, T.; Kaneko, N.; Amagane, H.; Someya, T. Supportive evidence for neuregulin 1 as a susceptibility gene for schizophrenia in a Japanese population. Neurosci. Lett. 2006, 396, 117–120. [Google Scholar] [CrossRef] [PubMed]
- Zanazzi, G.; Einheber, S.; Westreich, R.; Hannocks, M.-J.; Bedell-Hogan, D.; Marchionni, M.A.; Salzer, J.L. Glial Growth Factor/Neuregulin Inhibits Schwann Cell Myelination and Induces Demyelination. J. Cell Biol. 2001, 152, 1289–1300. [Google Scholar] [CrossRef] [PubMed]
- Cantó, C.; Chibalin, A.V.; Barnes, B.R.; Glund, S.; Suárez, E.; Ryder, J.W.; Palacín, M.; Zierath, J.R.; Zorzano, A.; Gumà, A. Neuregulins Mediate Calcium-induced Glucose Transport during Muscle Contraction. J. Biol. Chem. 2006, 281, 21690–21697. [Google Scholar] [CrossRef] [PubMed]
- Wang, X.-D.; Su, Y.-A.; Guo, C.-M.; Yang, Y.; Si, T.-M. Chronic antipsychotic drug administration alters the expression of neuregulin 1β, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus. Int. J. Neuropsychopharmacol. 2008, 11, 553–561. Available online: https://academic.oup.com/ijnp/article-lookup/doi/10.1017/S1461145707008371 (accessed on 7 June 2024). [CrossRef] [PubMed]
- Banerjee, A.; MacDonald, M.L.; Borgmann-Winter, K.E.; Hahn, C.-G. Neuregulin 1–erbB4 pathway in schizophrenia: From genes to an interactome. Brain Res. Bull. 2010, 83, 132–139. [Google Scholar] [CrossRef] [PubMed]
- Nicodemus, K.K.; Luna, A.; Vakkalanka, R.; Goldberg, T.; Egan, M.; Straub, R.E.; Weinberger, D.R. Further evidence for association between ErbB4 and schizophrenia and influence on cognitive intermediate phenotypes in healthy controls. Mol. Psychiatry 2006, 11, 1062–1065. [Google Scholar] [CrossRef] [PubMed]
- Norton, N.; Moskvina, V.; Morris, D.W.; Bray, N.J.; Zammit, S.; Williams, N.M.; Williams, H.J.; Preece, A.C.; Dwyer, S.; Wilkinson, J.C.; et al. Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006, 141B, 96–101. [Google Scholar] [CrossRef] [PubMed]
- Tian, J.; Geng, F.; Gao, F.; Chen, Y.-H.; Liu, J.-H.; Wu, J.-L.; Lan, Y.-J.; Zeng, Y.-N.; Li, X.-W.; Yang, J.-M.; et al. Down-Regulation of Neuregulin1/ErbB4 Signaling in the Hippocampus Is Critical for Learning and Memory. Mol. Neurobiol. 2017, 54, 3976–3987. [Google Scholar] [CrossRef] [PubMed]
- Huang, Y.Z.; Won, S.; Ali, D.W.; Wang, Q.; Tanowitz, M.; Du, Q.S.; Pelkey, K.A.; Yang, D.J.; Xiong, W.C.; Salter, M.W.; et al. Regulation of Neuregulin Signaling by PSD-95 Interacting with ErbB4 at CNS Synapses. Neuron 2000, 26, 443–455. [Google Scholar] [CrossRef]
- Fusar-Poli, P.; Papanastasiou, E.; Stahl, D.; Rocchetti, M.; Carpenter, W.; Shergill, S.; McGuire, P. Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophr. Bull. 2015, 41, 892–899. [Google Scholar] [CrossRef]
- Yang, J.; Kang, C.; Wu, C.; Lin, Y.; Zeng, L.; Yuan, J.; Zhang, Y.; Wei, Y.; Xu, L.; Zhou, F. Pharmacogenetic associations of NRG1 polymorphisms with neurocognitive performance and clinical symptom response to risperidone in the untreated schizophrenia. Schizophr. Res. 2021, 231, 67–69. [Google Scholar] [CrossRef] [PubMed]
- Tendilla-Beltrán, H.; Meneses-Prado, S.; Vázquez-Roque, R.A.; Tapia-Rodríguez, M.; Vázquez-Hernández, A.J.; Coatl-Cuaya, H.; Martín-Hernández, D.; MacDowell, K.S.; Garcés-Ramírez, L.; Leza, J.C.; et al. Risperidone Ameliorates Prefrontal Cortex Neural Atrophy and Oxidative/Nitrosative Stress in Brain and Peripheral Blood of Rats with Neonatal Ventral Hippocampus Lesion. J. Neurosci. 2019, 39, 8584–8599. [Google Scholar] [CrossRef] [PubMed]
- Chen, C.-Y.; Yeh, Y.-W.; Kuo, S.-C.; Ho, P.-S.; Liang, C.-S.; Yen, C.-H.; Lu, R.-B.; Huang, S.-Y. Catechol-O-methyltransferase gene variants may associate with negative symptom response and plasma concentrations of prolactin in schizophrenia after amisulpride treatment. Psychoneuroendocrinology 2016, 65, 67–75. [Google Scholar] [CrossRef] [PubMed]
- Nelson, C.L.M.; Amsbaugh, H.M.; Reilly, J.L.; Rosen, C.; Marvin, R.W.; Ragozzino, M.E.; Bishop, J.R.; Sweeney, J.A.; Hill, S.K. Beneficial and adverse effects of antipsychotic medication on cognitive flexibility are related to COMT genotype in first episode psychosis. Schizophr. Res. 2018, 202, 212–216. [Google Scholar] [CrossRef]
- Ma, J.; Zhao, M.; Zhou, W.; Li, M.; Huai, C.; Shen, L.; Wang, T.; Wu, H.; Zhang, N.; Zhang, Z.; et al. Association Between the COMT Val158Met Polymorphism and Antipsychotic Efficacy in Schizophrenia: An Updated Meta-Analysis. Curr. Neuropharmacol. 2021, 19, 1780–1790. [Google Scholar] [CrossRef] [PubMed]
- Nikolac Perkovic, M.; Sagud, M.; Zivkovic, M.; Uzun, S.; Nedic Erjavec, G.; Kozumplik, O.; Svob Strac, D.; Mimica, N.; Mihaljevic Peles, A.; Pivac, N. Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia. Sci. Rep. 2020, 10, 10049. [Google Scholar] [CrossRef] [PubMed]
- Hirasawa-Fujita, M.; Tudor, L.; Nikolac Pekovic, M.; Kozumplik, O.; Nedic Erjavec, G.; Uzun, S.; Svob Strac, D.; Konjevod, M.; Mimica, N.; Domino, E.; et al. Genotypic and haplotypic associations of catechol-O-methyltransferase (COMT) rs4680 and rs4818 with salivary cortisol in patients with schizophrenia. Psychiatry Res. 2018, 259, 262–264. [Google Scholar] [CrossRef] [PubMed]
- Elton, A.; Smith, C.T.; Parrish, M.H.; Boettiger, C.A. COMT Val158Met Polymorphism Exerts Sex-Dependent Effects on fMRI Measures of Brain Function. Front. Hum. Neurosci. 2017, 11, 578. [Google Scholar] [CrossRef]
- Frois, T.; Faria, L.O.; Souza, R.P.D.; Da Silva Cunha, A.E.; De Holanda Marinho Nogueira, N.G.; Tavares Lim, V.; De Sousa Fortes, L.; De Miranda, D.M.; Bertollo, M.; Albuquerque, M.R. Are COMT Val158Met (rs4680), DRD2 TaqIA (rs1800497), and BDNF Val66Met (rs6265) polymorphisms associated with executive functions performance at rest and during physical exercise? Physiol. Behav. 2022, 257, 113973. [Google Scholar] [CrossRef]
- Huang, E.; Zai, C.C.; Lisoway, A.; Maciukiewicz, M.; Felsky, D.; Tiwari, A.K.; Bishop, J.R.; Ikeda, M.; Molero, P.; Ortuno, F.; et al. Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: A Meta-Analysis. Int. J. Neuropsychopharmacol. 2016, 19, pyv132. [Google Scholar] [CrossRef]
- Han, J.; Li, Y.; Wang, X. Potential link between genetic polymorphisms of catechol-O-methyltransferase and dopamine receptors and treatment efficacy of risperidone on schizophrenia. Neuropsychiatr. Dis. Treat. 2017, 13, 2935–2943. [Google Scholar] [CrossRef] [PubMed]
- Kay, S.R.; Opler, L.A.; Lindenmayer, J.-P. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 1988, 23, 99–110. [Google Scholar] [CrossRef] [PubMed]
- Van Den Oord, E.J.C.G.; Rujescu, D.; Robles, J.R.; Giegling, I.; Birrell, C.; Bukszár, J.; Murrelle, L.; Möller, H.-J.; Middleton, L.; Muglia, P. Factor structure and external validity of the PANSS revisited. Schizophr. Res. 2006, 82, 213–223. [Google Scholar] [CrossRef] [PubMed]
- Leucht, S. Measurements of Response, Remission, and Recovery in Schizophrenia and Examples for Their Clinical Application. J. Clin. Psychiatry 2014, 75, 8–14. [Google Scholar] [CrossRef] [PubMed]
- Lin, Y.-J.; Cheng, C.-F.; Wang, C.-H.; Liang, W.-M.; Tang, C.-H.; Tsai, L.-P.; Chen, C.-H.; Wu, J.-Y.; Hsieh, A.-R.; Lee, M.T.M.; et al. Genetic Architecture Associated With Familial Short Stature. J. Clin. Endocrinol. Metab. 2020, 105, 1801–1813. [Google Scholar] [CrossRef] [PubMed]
- Sun, L.; Bull, S.B. Reduction of selection bias in genomewide studies by resampling. Genet. Epidemiol. 2005, 28, 352–367. [Google Scholar] [CrossRef] [PubMed]
- Kang, C.Y.; Xu, X.F.; Liu, H.; Shi, Z.Y.; Xu, H.H.; Yang, J.Z. Interaction of catechol-O-methyltransferase (COMT) Val108/158 Met genotype and risperidone treatment in Chinese Han patients with schizophrenia. Psychiatry Res. 2010, 176, 94–95. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Fang, Y.; Shen, Y.; Xu, Q. Analysis of association between the catechol-O-methyltransferase (COMT) gene and negative symptoms in chronic schizophrenia. Psychiatry Res. 2010, 179, 147–150. [Google Scholar] [CrossRef] [PubMed]
- Gupta, M.; Bhatnagar, P.; Grover, S.; Kaur, H.; Baghel, R.; Bhasin, Y.; Chauhan, C.; Verma, B.; Manduva, V.; Mukherjee, O.; et al. Association Studies of Catechol-O-Methyltransferase (COMT) Gene with Schizophrenia and Response to Antipsychotic Treatment. Pharmacogenomics 2009, 10, 385–397. [Google Scholar] [CrossRef]
- Herken, H.; Emin Erdal, M. Catechol-O-methyltransferase gene polymorphism in schizophrenia: Evidence for association between symptomatology and prognosis. Psychiatr. Genet. 2001, 11, 105–109. [Google Scholar] [CrossRef]
- Madzarac, Z.; Tudor, L.; Sagud, M.; Nedic Erjavec, G.; Mihaljevic Peles, A.; Pivac, N. The Associations between COMT and MAO-B Genetic Variants with Negative Symptoms in Patients with Schizophrenia. Curr. Issues Mol. Biol. 2021, 43, 618–636. [Google Scholar] [CrossRef] [PubMed]
- Molero, P.; Ortuño, F.; Zalacain, M.; Patiño-García, A. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: Influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J. 2007, 7, 418–426. [Google Scholar] [CrossRef]
- Chhabra, H.; Shivakumar, V.; Subbanna, M.; Bose, A.; Agrawal, M.; Sreeraj, V.S.; Kalmady, S.V.; Narayanaswamy, J.C.; Debnath, M.; Venkatasubramanian, G. Influence of COMT and NRG-1 gene polymorphisms on the effect of tDCS on Auditory Verbal Hallucinations in Schizophrenia. Brain Stimulat. 2017, 10, 410–411. [Google Scholar] [CrossRef]
- Mostaid, M.S.; Lloyd, D.; Liberg, B.; Sundram, S.; Pereira, A.; Pantelis, C.; Karl, T.; Weickert, C.S.; Everall, I.P.; Bousman, C.A. Neuregulin-1 and schizophrenia in the genome-wide association study era. Neurosci. Biobehav. Rev. 2016, 68, 387–409. [Google Scholar] [CrossRef] [PubMed]
- Kampman, O.; Anttila, S.; Illi, A.; Saarela, M.; Rontu, R.; Mattila, K.M.; Leinonen, E.; Lehtimäki, T. Neuregulin genotype and medication response in Finnish patients with schizophrenia. NeuroReport 2004, 15, 2517–2520. [Google Scholar] [CrossRef]
- Schmitt, A.; Koschel, J.; Zink, M.; Bauer, M.; Sommer, C.; Frank, J.; Treutlein, J.; Schulze, T.; Schneider-Axmann, T.; Parlapani, E.; et al. Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2010, 260, 101–111. [Google Scholar] [CrossRef]
- Moradkhani, A.; Turki Jalil, A.; Mahmood Saleh, M.; Vanaki, E.; Daghagh, H.; Daghighazar, B.; Akbarpour, Z.; Ghahramani Almanghadim, H. Correlation of rs35753505 polymorphism in Neuregulin 1 gene with psychopathology and intelligence of people with schizophrenia. Gene 2023, 867, 147285. [Google Scholar] [CrossRef] [PubMed]
- Lubis, B.M.; Effendi, S.H.; Ganie, R.A.; Ramayani, O.R. Impact of the Neuregulin rs35753505 C/T Polymorphisms on Neuregulin 1 Levels in Preterm Infants. Open Access Maced. J. Med. Sci. 2019, 7, 1931–1934. [Google Scholar] [CrossRef]
- Yang, H.; Pan, W.; Xiao, W.; Yang, M.; Xu, J.; Li, J.; Zhang, X. Antipsychotic drugs increase Neuregulin1β1 serum levels in first-episode drug-naïve patients and chronic schizophrenia with suggestions for improving the treatment of psychotic symptoms. BMC Psychiatry 2022, 22, 217. [Google Scholar] [CrossRef]
- Marchesi, C.; Affaticati, A.; Monici, A.; De Panfilis, C.; Ossola, P.; Tonna, M. Predictors of symptomatic remission in patients with first-episode schizophrenia: A 16years follow-up study. Compr. Psychiatry 2014, 55, 778–784. [Google Scholar] [CrossRef]
- Sargazi, S.; Heidari Nia, M.; Sheervalilou, R.; Mirinejad, S.; Harati-Sadegh, M.; Moudi, M.; Saravani, R.; Shakiba, M. Relationship between Single Nucleotide Polymorphisms of GRHL3 and Schizophrenia Susceptibility: A Preliminary Case-Control Study and Bioinformatics Analysis. Int. J. Mol. Cell. Med. 2020, 9. [Google Scholar] [CrossRef]
- Heidari Nia, M.; Jafari Shahroudi, M.; Saravani, R.; Sargazi, S.; Moudi, M.; Mojahed, A. Relationship between P2XR4 Gene Variants and the Risk of Schizophrenia in South-East of Iran: A Preliminary Case-Control Study and in Silico Analysis. Iran. J. Public Health 2021. Available online: https://publish.kne-publishing.com/index.php/ijph/article/view/6115. (accessed on 11 June 2024). [CrossRef] [PubMed]
- Kircher, T.; Thienel, R.; Wagner, M.; Reske, M.; Habel, U.; Kellermann, T.; Frommann, I.; Schwab, S.; Wölwer, W.; Von Wilmsdorf, M.; et al. Neuregulin 1 ICE-single nucleotide polymorphism in first episode schizophrenia correlates with cerebral activation in fronto-temporal areas. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259, 72–79. [Google Scholar] [CrossRef] [PubMed]
Variables | Non-Responders (n = 47) | Responders (n = 56) | p-Value |
---|---|---|---|
Age (mean ± SD) | 40 ± 13 | 40 ± 14 | 0.95 |
Sex | 47 | 56 | 1 |
Male | 51% (24) | 52% (29) | |
Female | 49% (23) | 48% (27) | |
Education (years of study) (mean ± SD) | 12 ± 3 | 12 ± 3 | 0.73 |
Occupation | 0.06 | ||
Student | 6% (3) | 9% (5) | |
Employed | 34% (11) | 44% (25) | |
Unemployed | 34% (16) | 20% (11) | |
Retired | 2% (1) | 7% (4) | |
Ill-health Retired | 34% (16) | 20% (11) |
Variables | Non-Responders (n = 47) | Responders (n = 56) | p-Value |
---|---|---|---|
Age of onset (years) (mean ± SD) | 33 ± 13 | 33 ± 13 | 0.77 |
Number of episodes (mean ± SD) | 4 ± 5 | 3 ± 3 | 0.49 |
Dose/day (mg) (mean ± SD) | 4 ± 1 | 5 ± 2 | 0.32 |
Diagnostic | 0.49 | ||
Schizophreniform disorder | 49% (23) | 52% (29) | |
Schizophrenia | 17% (8) | 21% (12) | |
Schizoaffective disorder | 15% (7) | 18% (10) | |
Delusional Disorder | 19% (9) | 9% (5) | |
PANSS T0 (mean ± SD) | |||
PANSS P T0 | 26 ± 6 | 24 ± 6 | 0.09 |
PANSS N T0 | 19 ± 6 | 21 ± 7 | 0.54 |
PANSS G T0 | 48 ± 9 | 51 ± 9 | 0.10 |
PANSS T T0 | 94 ± 14 | 97 ± 15 | 0.23 |
PANSS T6 (mean ± SD) | |||
PANSS P T6 | 21 ± 5 | 15 ± 3 | 0.001 |
PANSS N T6 | 17 ± 5 | 15 ± 5 | 0.05 |
PANSS G T6 | 41 ± 8 | 35 ± 8 | 0.001 |
PANSS T T6 | 80 ± 13 | 64 ± 10 | 0.001 |
COMT (rs4680) | 47 | 56 | 0.21 |
AA | 12 (26%) | 18 (32%) | |
AG | 24 (51%) | 32 (57%) | |
GG | 11 (23%) | 6 (11%) | |
NRG1 (rs35753505) | 0.55 | ||
CC | 3 (6%) | 4 (7%) | |
CT | 20 (43%) | 18 (32%) | |
TT | 24 (51%) | 34 (61%) | |
NRG1 (rs3924999) | 0.77 | ||
AA | 6 (13%) | 9 (16%) | |
AG | 25 (53%) | 26 (46%) | |
GG | 16 (34%) | 21 (38%) |
*ΔPANSS G for Genotypes of COMT rs4680 | diff | lwr | upr | p-adj |
---|---|---|---|---|
AG-AA | −3.05 | −7.29 | 1.18 | 0.2 |
GG-AA | −5.65 | −11.34 | 0.03 | 0.05 |
GG-AG | −2.59 | −7.78 | 2.58 | 0.46 |
*ΔPANSS N for Genotypes of COMT rs4680 | Z-Value | p-adj |
---|---|---|
AA-AG | −2.52 | 0.03 |
AA-GG | −1 | 0.89 |
AG-GG | 0.92 | 1 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bondrescu, M.; Dehelean, L.; Farcas, S.S.; Papava, I.; Nicoras, V.; Mager, D.V.; Grecescu, A.E.; Podaru, P.A.; Andreescu, N.I. COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy. Biomolecules 2024, 14, 777. https://doi.org/10.3390/biom14070777
Bondrescu M, Dehelean L, Farcas SS, Papava I, Nicoras V, Mager DV, Grecescu AE, Podaru PA, Andreescu NI. COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy. Biomolecules. 2024; 14(7):777. https://doi.org/10.3390/biom14070777
Chicago/Turabian StyleBondrescu, Mariana, Liana Dehelean, Simona Sorina Farcas, Ion Papava, Vlad Nicoras, Dana Violeta Mager, Anca Eliza Grecescu, Petre Adrian Podaru, and Nicoleta Ioana Andreescu. 2024. "COMT and Neuregulin 1 Markers for Personalized Treatment of Schizophrenia Spectrum Disorders Treated with Risperidone Monotherapy" Biomolecules 14, no. 7: 777. https://doi.org/10.3390/biom14070777